Studies with the 68Ga-labeled anti-HER2 Affibody molecule ABY-025 PET have shown that increases in injected mass from 78 ± 8 to 427 ± 19 μg improved the discrimination between liver background and tumor lesions, presumably due to decreasing the binding to hepatocytes and increasing the bioavailability of the tracer 15. This evidence concerns the gene ERBB2 and neoplasm.